HIV disease is becoming more of a chronic condition in countries with good access to medical care. In the area of NeuroAIDS there is no acknowledged, useful biomarker for the cognitive disorder associated with HIV disease (i.e., HIV-Associated Neurocognitive Disorder (HAND)), independent of the cognitive tests. Magnetic resonance imaging and positron emission tomography have been tried, but have yet to fulfill their promise {Price, 2007 #6509}. One emerging technology that has only recently been applied to HIV Disease - by our research team - is magnetoencephalography (MEG). MEG is a non-invasive technique for measuring neuronal activity by recording the magnetic fields induced by synchronized neuronal currents. MEG has the highest spatial and temporal resolution of any current neuroimaging technology, and is used most commonly in the clinical evaluation of patients with seizure disorders, and by cognitive neuroscientists to investigate electrophysiological responses of the CNS. Unlike techniques such as functional MRI, MEG does not rely on the blood-oxygen level dependent response in order to generate responses. Thus, it will be very important to determine whether MEG can identify abnormal brain function in HIV Disease - especially when cognitive dysfunction is mild and not yet affecting activities of daily living. Our team has demonstrated that we can differentiate infected from uninfected study subjects, that there may be an independent MEG-derived variable that is sensitive to cognitive dysfunction, and that MEG signals are stable over a 6-month period. The preliminary research was conducted in the context of an R03-funded study, so the overall goal of this new R21 research project is to obtain the necessary additional data from 30 infected individuals (and 10 controls) to finalize the design for a larger, longitudinal study. These data will allow us to begi to characterize the neurocognitive outcomes of HIV Disease using a highly sensitive electrophysiological tool.

Public Health Relevance

HIV infected patients can still have abnormalities in cognition ranging from the more common mild deficits, to the less common, but more devastating dementia. What is missing in the field of NeuroAIDS is a tool that will provide information about the biological state of the brain that is related to the cognitive impairment. We propose to study Magnetoencephalography (MEG) as a potential biomarker. In this project, we will find out whether it is feasible to use MEG in patients with NeuroAIDS, and we will decide exactly how to design a larger, longitudinal study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH098745-02
Application #
8549303
Study Section
Special Emphasis Panel (ZRG1-AARR-C (02))
Program Officer
Brouwers, Pim
Project Start
2012-09-21
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$178,079
Indirect Cost
$58,079
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Becker, James T; Martinson, Jeremy J; Penugonda, Sudhir et al. (2015) No association between Apo?4 alleles, HIV infection, age, neuropsychological outcome, or death. J Neurovirol 21:24-31
Becker, James T; Kingsley, Lawrence A; Molsberry, Samantha et al. (2015) Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. Int J Epidemiol 44:1506-16
Hernandez, Isabel; Mauleon, Ana; Rosense-Roca, Maitee et al. (2014) Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses. Curr Alzheimer Res 11:182-91
Pineda-Pardo, José Angel; Garcés, Pilar; López, María Eugenia et al. (2014) White matter damage disorganizes brain functional networks in amnestic mild cognitive impairment. Brain Connect 4:312-22
Becker, James T; Snitz, Beth E (2013) Yes, it is time to reconsider how we rate cognitive impairments in HIV disease. Neuroepidemiology 41:217-8